Home/Pipeline/Lidocaine Topical System 1.8%

Lidocaine Topical System 1.8%

Postherpetic Neuralgia (PHN)

ApprovedCommercial

Key Facts

Indication
Postherpetic Neuralgia (PHN)
Phase
Approved
Status
Commercial
Company

About Mayne Pharma Group

Mayne Pharma Group is an Australian specialty pharmaceutical company with a dual focus on developing novel drug delivery technologies and commercializing a portfolio of branded and generic products. The company has built a substantial US commercial platform through acquisitions and leverages its in-house development and manufacturing capabilities. Its strategic direction centers on expanding its women's health franchise, optimizing its commercial portfolio, and advancing its pipeline of complex generic and 505(b)(2) products.

View full company profile

Other Postherpetic Neuralgia (PHN) Drugs

DrugCompanyPhase
LX9211Lexicon PharmaceuticalsPhase 2
ZTlido®Aytu BioScienceApproved/Commercial